Letter to the editor regarding ‘A systemic review and meta-analysis on the efficacy and safety of ferumoxytol for anemia in chronic kidney disease patients’

Linqiang LiDepartment of Internal Medicine, Tongxiang Chinese Medicine Hospital, Tongxiang, ChinaCorrespondence[email protected]
View further author information

Huiqin FengDepartment of Internal Medicine, Tongxiang Chinese Medicine Hospital, Tongxiang, ChinaView further author information

References

Zuo Q, Wang T, Zhu L, et al. A systemic review and meta-analysis on the efficacy and safety of ferumoxytol for anemia in chronic kidney disease patients. Ren Fail. 2022;44(1):94–102.
PubMed Web of Science ®Google Scholar
Lu M, Cohen MH, Rieves D, et al. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010;85(5):315–319.
PubMed Web of Science ®Google Scholar
Singh A, Patel T, Hertel J, et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis. 2008;52(5):907–915.
PubMed Web of Science ®Google Scholar
Strauss WE, Dahl NV, Li Z, et al. Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia. BMC Hematol. 2016;16:20.
PubMedGoogle Scholar
Macdougall IC, Strauss WE, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol. 2014;9(4):705–712.
PubMed Web of Science ®Google Scholar